局部七氟烷治疗慢性创面的疗效:一项非随机对照研究

注册号:

Registration number:

ChiCTR2600121207 

最近更新日期:

Date of Last Refreshed on:

2026-03-26 17:13:52 

注册时间:

Date of Registration:

2026-03-26 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

局部七氟烷治疗慢性创面的疗效:一项非随机对照研究

Public title:

Efficacy of topical sevoflurane in the treatment of chronic wounds: a non-randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

局部应用七氟烷治疗创面的临床研究

Scientific title:

Clinical study of topical application of sevoflurane in the treatment of wounds

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐薇 

研究负责人:

储勤军 

Applicant:

Wei Xu  

Study leader:

Qinjun Chu  

申请注册联系人电话:

Applicant telephone:

+86 156 2604 4364

研究负责人电话:

Study leader's
telephone:

+86 138 3810 0696

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

107534090@qq.com

研究负责人电子邮件:

Study leader's E-mail:

jimmynetchu@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国河南省郑州市中原区桐柏北路16号

研究负责人通讯地址:

中国河南省郑州市中原区桐柏北路16号

Applicant address:

No. 16, Tongbai North Road, Zhongyuan District, Zhengzhou City, Henan Province, China

Study leader's address:

No. 16, Tongbai North Road, Zhongyuan District, Zhengzhou City, Henan Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

郑州大学附属郑州中心医院

Applicant's institution:

Zhengzhou Central Hospital Affiliated to Zhengzhou University

研究负责人所在单位:

郑州大学附属郑州中心医院

Affiliation of the Leader:

Zhengzhou Central Hospital Affiliated to Zhengzhou University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ZXYY2024150

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

郑州市中心医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Zhengzhou Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-08-29 00:00:00

伦理委员会联系人:

龚老师

Contact Name of the ethic committee:

Ms. Gong

伦理委员会联系地址:

中国河南省郑州市中原区桐柏北路16号

Contact Address of the ethic committee:

No. 16, Tongbai North Road, Zhongyuan District, Zhengzhou City, Henan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 152 3962 7550

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

郑州大学附属郑州中心医院

Primary sponsor:

Zhengzhou Central Hospital Affiliated to Zhengzhou University

研究实施负责(组长)单位地址:

中国河南省郑州市中原区桐柏北路16号

Primary sponsor's address:

No. 16, Tongbai North Road, Zhongyuan District, Zhengzhou City, Henan Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南省

市(区县):

Country:

China

Province:

Henan

City:

单位(医院):

郑州大学附属郑州中心医院

具体地址:

中国河南省郑州市中原区桐柏北路16号

Institution
hospital:

Zhengzhou Central Hospital Affiliated to Zhengzhou University

Address:

No. 16, Tongbai North Road, Zhongyuan District, Zhengzhou City, Henan Province, China

经费或物资来源:

自筹

Source(s) of funding:

Self-raised by the researcher

研究疾病:

慢性创面  

Target disease:

Chronic wound

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究对将七氟烷局部应用于创面,旨在探究七氟醚用于治疗创面具有一系列治疗益处,包括缓解局部疼痛、促进伤口愈合。  

Objectives of Study:

The aim of this study is to explore the therapeutic benefits of sevoflurane in the treatment of wounds, including relieving local pain and promoting wound healing.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并恶性肿瘤或严重感染伴随全身症状,有自身免疫性疾病或服用免疫抑制剂者; 2.妊娠或哺乳期妇女; 3.近 3 个月内参与其他相关临床试验者; 4.恶性高热史和倾向者; 5.根据研究者判断,受试者不可信或依从性差者

Exclusion criteria:

1. Patients with malignant tumors or severe infections accompanied by systemic symptoms, autoimmune diseases or immunosuppressants; 2. Pregnant or lactating women; 3. Those who participated in other relevant clinical trials within the past 3 months; 4. patients with malignant high fever history and tendency; 5. Subjects were unreliable or had poor compliance according to the investigator's judgment

研究实施时间:

Study execute time:

From 2024-08-30 00:00:00 To 2025-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-30 00:00:00 To 2024-12-02 00:00:00

干预措施:

Interventions:

组别:

标准治疗组

样本量:

51

Group:

Standard of Care

Sample size:

干预措施:

对创面常规清创换药。

干预措施代码:

Intervention:

Routine debridement and dressing change were performed for the wounds.

Intervention code:

组别:

七氟烷+标准治疗组

样本量:

51

Group:

Standard of Care plus Sevoflurane

Sample size:

干预措施:

进行创面常规清创换药治疗的同时,采用七氟烷局部冲洗。

干预措施代码:

Intervention:

Routine debridement and dressing change were performed for the wounds, combined with topical irrigation of sevoflurane.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南省 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

郑州大学附属郑州中心医院豫欣老年病医院 

单位级别:

二级 

Institution
hospital:

Yuxin Geriatric Hospital, Zhengzhou Central Hospital affiliated to Zhengzhou University

Level of the institution:

Secondary

测量指标:

Outcomes:

指标中文名:

创面愈合率

指标类型:

主要指标

Outcome:

The wound healing rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛强度

指标类型:

次要指标

Outcome:

Pain Intensity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

恶心

指标类型:

副作用指标

Outcome:

Nausea

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头晕

指标类型:

副作用指标

Outcome:

Dizziness

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瘙痒

指标类型:

副作用指标

Outcome:

Pruritus

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

红斑

指标类型:

副作用指标

Outcome:

Erythema

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮炎

指标类型:

副作用指标

Outcome:

Dermatitis

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 21 years
最大 Max age 93 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

无。

Randomization Procedure (please state who generates the random number sequence and by what method):

None.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据将于文章发表6个月后公开,上传至临床试验公共管理平台 ResMan(www.medresman.org)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be uploaded to the public platform of the China Clinical Trial Registry (https://www.chictr.org.cn/) for sharing six months after the article's publication.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究通过医院病历系统和纸质病例报告表(CRF)采集数据。经统一培训的研究人员依据病历和现场评估填写CRF。数据经审核后,由双人独立录入电子数据库(如Excel)并进行一致性核对。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data for this study were collected using the hospital medical record system and paper-based case report forms (CRFs). Uniformly trained research personnel completed the CRFs based on patient medical records and on-site assessments. Following data review, the information was independently entered into an electronic database (e.g., Excel) by two individuals and cross-checked for consistency.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-03-26 17:13:35